Table 2.

Overview of the retrospective evaluation and recommendations for improvements.

Patient	Indication	First response	Dosing regimen	ADRs a	Potential improvements with bedside availability
A	Correct	Responder	Dose-response relationship	Increased heart rate variability	Start therapy earlier to prevent hypoxia and decrease dosage every 12 h to prevent overtreatment
B	Correct	Non-responder	Overtreatment	Increased agitation	Stop therapy earlier to prevent hypoxia and overtreatment with ADRs
C	Correct	Responder	Dose-response relationship	No ADRs observed	Evaluate therapy effect at least every 12 h and increase dosage to prevent hypoxia
D	Incorrect	Responder	Overtreatment	No ADRs observed	Do not start doxapram therapy, and decrease dosage every 12 h to prevent overtreatment
E	Correct	Potential responder	Potential dose-response relationship	Increased heart rate	Stop therapy earlier to prevent hypoxia and overtreatment with ADRs
F	Correct	Non-responder	Overtreatment	Increased agitation	Stop therapy earlier to prevent hypoxia and overtreatment with ADRs
G	Probably correct	Responder	Overtreatment	No ADRs observed	Decrease dosage every 12 h to prevent overtreatment
H	Probably incorrect	Potential responder	Potential dose-response relationship	No ADRs observed	Evaluate therapy effect at least every 12 h to prevent hypoxia

^aPossible adverse drug reaction (ADR).